10 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen

Page 4 of 4

6. Guardant Health, Inc. (NASDAQ:GH)

Point72 Asset Management: $153,125,122

On May 8, Evercore ISI analyst Vijay Kumar raised Guardant Health, Inc. (NASDAQ:GH)’s price objective to $95 from $90. It kept an “In Line” rating on the shares.

On May 7, Guardant Health, Inc. (NASDAQ:GH) released its Q1 2026 financial report. The revenue was $301.7 million, marking a 48% YoY growth. The firm credited the rise to oncology sales of $205.0 million, up by 36%, while the biopharma and data revenue surged by 17%. The screening revenue came in at $41.6 million.

The company had a non-GAAP gross margin of 66% and improved from 65%. It had a gross profit of $196.7 million, soaring by 53%. Guardant Health also reported a net loss of $112.1 million, up from $95.2 million.

Helmy Eltoukhy, co-founder and co-CEO, said the revenue increase simply shows “strong momentum.” The oncology test volume climbed by 47% to 86,000 tests. Meanwhile, co-founder and co-CEO AmirAli Talasaz noted that Shield volume momentum helps future growth.

Guardant Health, Inc. (NASDAQ:GH) also upgraded its revenue outlook for 2026 to $1.30 billion to $1.32 billion, representing growth of 32% to 34%.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology firm. It provides cancer treatment using blood tests, data sets, and analytics.

While we acknowledge the potential of GH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GH and that has 100x upside potential, check out our report about the cheapest AI stock.

Click to continue reading and see the 5 Best Biotech Stocks to Invest In According to Billionaire Steve Cohen.

Disclosure: None. Follow Insider Monkey on Google News.

Page 4 of 4